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Abstract The mechanism of the inhibition of sheep liver sorbitol 
dehydrogenase by the novel antidiabetogenic drug 2-hydroxy-
methy]-4-(4-./V,ALdimethylaminosulfonyl-l-piperazino)pyrimi-
dine has been investigated by steady-state kinetics over the range 
pH 5-10. The pyrimidine derivative exhibits mixed inhibition 
with respect to sorbitol, fructose and coenzyme, due to the 
formation of enzyme-inhibitor and enzyme-NAD(H)-inhibitor 
complexes. The formation of each of the binary and ternary 
complexes is inhibited by protonation and deprotonation of 
groups which, in the enzyme-inhibitor complex, have fK values of 
6.6 and 8.0, respectively. 
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1. Introduction 
Sorbitol dehydrogenase (SDH) is a homotetrameric zinc 
enzyme of 38 kDa subunits present in most mammalian tis-
sues [1]. The enzyme belongs to a family of dehydrogenases/ 
reductases which also includes several classes of alcohol de-
hydrogenases (ADH), ζ-crystallin and numerous other pro-
teins [2]. Although data on the three-dimensional structure 
and functionally significant residues, apart from the zinc li-
gands Cys43, His68 and Glu149 [3], are unavailable, a model 
has been constructed for the subunit structure of sheep liver 
SDH on the basis of the crystal structure of the related horse 
liver ADH and sequence alignment [4]. Crystallographic stud-
ies on sheep liver SDH are in progress (H. Eklund, unpub-
lished results). 
Aldose reducíase (AR) and SDH constitute the sorbitol, or 
polyol, pathway [5], which catalyzes the conversion of glucose 
to fructose via sorbitol: 
, AR 
glucose + NADPH + H+ ^ sorbitol + NADP+ 
SDH 
sorbitol + NAD+ ^ fructose + NADH + H+. 
The increased flux via the pathway in hyperglycemia, as in 
poorly controlled diabetes mellitus, has been implicated in the 
etiology of diabetic complications [6]. Pathogenesis in some 
tissues, such as lens, has been attributed to sorbitol accumu-
lation and concomitant osmotic anomalies [7], and AR inhib-
itors have been used for many years in the treatment of dia-
betic complications [8]. However, recently the clinically 
beneficial effects of the novel SDH inhibitor 2-hydroxymeth-
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yl-4-(4-Ar,Af-dimethylaminosulfonyl-1 -piperazino) pyrimidine 
(SDI 158) in diabetic rat tissues were reported [9,10]. 
Although the inhibition of SDH aggravated sorbitol accumu-
lation it also alleviated, or attenuated, various complications, 
including impaired nerve conduction and vascular dysfunction 
in nerve, aorta and ocular tissues, without side effects. This 
implies that pathogenesis in these tissues is more closely asso-
ciated with oxidation of sorbitol to fructose, catalyzed by 
SDH, than with reduction of glucose to sorbitol. Thus, an 
elevated NADH/NAD ratio appears to be the single most 
important determinant of pathogenesis in various diabetic tis-
sues [10]. SDI 158 has recently also been reported to inhibit 
the SDH-catalyzed oxidation of sorbitol to fructose, thereby 
inhibiting glucokinase, in non-diabetic rat hepatocytes [11]. 
Whereas SDI 158 weakly inhibits AR, the compound has 
no effect on the activities of numerous other enzymes, includ-
ing hexokinase, glutathione reductase, glucose-6-phosphate 
dehydrogenase, lactate dehydrogenase and alcohol dehydro-
genase [9,10], indicating that SDI 158 is a specific inhibitor of 
SDH. The related compound 2-methyl-4-(4-7V,Ar-dimethylami-
nosulfonyl-1 -piperazino) pyrimidine (SDI 157) inhibits SDH 
poorly in vitro, and appears to be a prodrug [10]. 
At present, many investigators are attempting the synthesis 
of potent and specific SDH inhibitors for prospective use as 
drugs. SDI 158 is the only inhibitor clinically evaluated thus 
far and, in view of the few and inconclusive kinetic data 
previously published [9,10], the object of the present study 
was to investigate the mechanism for the inhibition of SDH 
by this compound. 
2. Materials and methods 
2.1. Materials 
Lyophilized sheep liver SDH was obtained from Boehringer and 
stock enzyme solutions were prepared by equilibrium dialysis, as de-
scribed previously [12]. The dialysed enzyme solutions were homoge-
neous upon starch gel electrophoresis and had a purity 2:98%. The 
concentration of active enzyme in solution was determined spectro-
photometrically, as previously described [12]. Stock enzyme solutions 
were stable for several days at 4°C. 
Sorbitol, D-fructose, NAD, NADH and piperazine were obtained 
from Sigma. All reagents were of p.a. quality and solutions were 
prepared in Milli-Q water. NADH was dissolved in 10 mM sodium 
phosphate, pH 7.4, because of the instability of the coenzyme in acid 
media. SDI 158 (pK=5.9) was supplied by Hoechst AG, Frankfurt 
am Main. The compound shows high solubility in water and is stable 
in aqueous solution. Stock solutions of SDI 158 were kept in the dark 
at 4°C. 
2.2. Kinetic measurements 
The initial rate of NAD-linked oxidation of sorbitol or NADH-
linked reduction of fructose was determined at 23.5°C by measuring 
the change in absorbance at 340 nm due to NAD reduction or NADH 
oxidation, using a Philips PU 8675 spectrophotometer connected to 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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Fig. 1. Reversible inhibition of sheep liver sorbitol dehydrogenase by SDI 158 at pH 7.4. A: Double-reciprocal plots showing the effect of SDI 
158 on the initial rate of sorbitol oxidation. [NAD] = 500 μΜ; without inhibitor (o), [SDI 158] = 0.50 μΜ (·), 1.0 μΜ (D). B: Double-recipro-
cal plots showing the effect of SDI 158 on the initial rate of fructose reduction. [NADH] = 50 μΜ; without inhibitor (o), [SDI 158]= 1.0 μΜ 
(·), 2.0 μΜ (D). C: Double-reciprocal plots showing the effect of SDI 158 on the initial rate of sorbitol oxidation, [sorbitol] = 10 mM; without 
inhibitor (o), [SDI 158] = 0.60 μΜ (·), 1.2 μΜ (D). D: Double-reciprocal plots showing the effect of SDI 158 on the initial rate of fructose re-
duction. [fructose] = 100 mM; without inhibitor (o), [SDI 158]= 1.0 μΜ (·), 2.0 μΜ (D). In each case, e denotes the concentration of enzyme 
(M) and v is the initial velocity (m s-1). 
an ABB Goertz SE 120 recorder. Reversible kinetics were performed 
by varying the concentration of sorbitol, fructose, NAD or NADH, 
with a constant concentration of the other reaction partner, in a total 
volume of 3.0 ml of 50 mM sodium phosphate, pH < 8.0, or 50 mM 
glycine/NaOH, pH>9.0 [13]. Two different [SDI 158] were used in 
each case in order to determine the kinetic inhibition constants. The 
relative standard deviations for the kinetic constants obtained by re-
gression analysis of the primary data were £10%. 
3. Results and discussion 
SDI 158 is a potent mixed inhibitor of the SDH-catalyzed 
oxidation of sorbitol and reduction of fructose. Fig. 1 shows 
the mixed inhibition patterns in double-reciprocal plots at pH 
7.4 with varied concentrations of sorbitol (a), fructose (b), 
NAD (c) and NADH (d). In each case, the inhibition con-
stants derived from the slope and intercept effects (see below) 
with two different inhibitor concentrations agreed to within 
the experimental error, indicating a simple, linear relationship 
between [SDI 158] and the inhibitory effect. 
Sorbitol oxidation and fructose reduction catalyzed by 
sheep liver SDH follow a compulsory ordered (Theorell-
Chance) kinetic mechanism, with only the coenzymes forming 
binary complexes with the free enzyme in each direction and 
the enzyme-coenzyme product dissociation as the rate-limiting 
step for the overall reaction [14]. The kinetic mechanism of 
sheep liver SDH can be depicted as in scheme 1: 
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E + O P EO + sorbitol ^ 
k- i k -
fructose + E R ¡^ E + R 
where E — enzyme, O = N A D and R = N A D H . The initial rate 
equation for the mechanism may be written: e/v = <E>o+Oi/ 
[NAD]+02 /[sorbitol]+Oi2 /[NAD][sorbitol], where the kinetic 
coefficients (Φ), which previously have been determined over 
the range p H 5-10 [14], are related to the rate constants (k) in 
scheme 1 through Φο = l / k ' - i , Φι = 1/k+i, Φ2 = l /k+ 2 and 
Oi2 = k - i / k+ i k+2. Because of the symmetry of the mecha-
nism, the initial rate equations for the forward and reverse 
reactions are interchangeable by the insertion or deletion of 
primes on the Φ coefficients. 
The slope effects vs. varied [NAD] reflect formation of an 
enzyme-inhibitor (El) binary complex (Fig. 1C). Because the 
Φι and Φ12 terms are similarly affected by the binding of 
inhibitor to the free enzyme, it follows that K E I = [I]/((S¡/ 
So)—1), where S¡ and So are the slopes in double-reciprocal 
plots with and without inhibitor, respectively. The slope ef-
fects vs. varied [sorbitol] reflect formation of an E l and/or 
enzyme-NAD-inhibitor (EOI) complex (Fig. 1A), affecting 
the Φ12 and Φ2 terms, respectively. When ΚΕ, Ι is known, 
ΚΕΟ,Ι can be computed [15] using the relationship 
KEO^I = [Ι]/[(1/Φ2) ( S Í - ( O I 2 / [ N A D ] X 1 + [ I ] / K E , I ) ) - 1 ] · The inter-
cept effects vs. varied [NAD] reflect formation of an EOI and/ 
or enzyme-NADH-inhibi tor (ERI) complex affecting the Φ 2 
and Φο terms, respectively. With sorbitol as the varied sub-
strate, the intercept effects represent an E l and/or E R I com-
plex affecting, respectively, the Φι and Φο terms. When KEji 
and ΚΕΟ,Ι are known, KER,I can be computed [15] using 
the relationships KE R , i = [Ι]/[(1/Φ0) ( I i -^ 2 / [ so rb i to l ] ) ( l+ [ I ] / 
K E o , i ) ) - l ] for fixed [sorbitol] and KER ,i = [Ι]/[(1/Φ0) ( Ι ί~(Φι / 
[ΝΑΕ>])(1+[Ι]/ΚΕ,ι))-1] for fixed [NAD], where I¡ is the inhib-
ited intercept in a double-reciprocal plot. Due to the symme-
try of the mechanism (scheme 1), the inhibited slopes and 
intercepts with varied [NADH] represent ΚΕ, Ι and ΚΕΟ, Ι / 
KER.L· respectively. With fructose as the varied substrate, the 
inhibited slopes represent KE, I /KER, I and the inhibited inter-
cepts are ΚΕ, Ι /ΚΕΟ,Ι - Whereas ΚΕ, Ι measures the affinity of 
SDI 158 for the free enzyme, ΚΕΟ,Ι a n d KER,I measure the 
affinity of the inhibitor for the enzymic binding site in the EO 
and ER complexes, respectively. Likewise, ΚΕΙ,Ο and KEI,R 
measure the affinity of the coenzymes for the E l complex. 
The latter constants were calculated using the relationships 
ΚΕΙ,Ο = ΚΕΟ, Ι -ΚΕ,Ο/ΚΕ, Ι and K E I , R = K E R , I - K E , R / K E , I . The val-
ues of ΚΕ,Ο and KE,R have previously been determined over 
the range p H 5-10 [14]. 
Table 1 lists the kinetic constants for the mixed inhibition 
of sheep liver S D H by DI 158 over the range p H 5.5-9.9. KE,i 
always represents the inhibited slopes with respect to 
N A D ( H ) , and as the EOI complex is not kinetically significant 
at p H < 7.4, the inhibited slopes with respect to sorbitol also 
represent ΚΕ, Ι at low pH. The similar constants derived from 
the intercept effects with respect to N A D and sorbitol repre-
sent KER,I in both cases. The proposed kinetic mechanism for 
the mixed inhibition of sorbitol oxidation and fructose reduc-
tion by SDI 158 can be depicted as follows: 
k+i k+2 k ' - i 
E + O · = ^ - EO + sorbitol —^- fructose + ER ^ = 
k-2 
*ΈΟ,Ι 
k ' + i 
El EOI 
N 





E + R + I 
E + R 
El 
In each direction, SDI 158 inhibits the steady-state rate of 
catalysis by combining with the free enzyme and with the 
holoenzyme substrate, and the additional binding of inhibitor 
to the holoenzyme product gives a ternary complex dissociat-
ing more slowly than the normally rate-limiting enzyme-coen-
zyme product dissociation (i.e. k ' - i * < k ' - i or k - i * < k - i ) . 
Previously, SDI 158 was reported to inhibit sorbitol oxida-
tion uncompetitively with respect to sorbitol and N A D with, 
in both cases, an inhibition constant of 0.19 μ Μ [10], which 
should be KER,T. Although no details regarding p H or exper-
imental procedures were given, this appears to agree with the 
present results, insofar as the same value for the inhibition 
constant (KER, I ) was obtained from the intercept effects with 
respect to both N A D and sorbitol. The present study also 
accords with the inhibition patterns of Geisen and co-workers 
[9] who, on the basis of Dixon plots, reported an apparent 
inhibition constant of 3.7 μ Μ at p H 9.5 with sorbitol as the 
varied substrate. Double-reciprocal plots of the latter data 
reveal mixed inhibition with respect to sorbitol, indicating 
formation of El , EOI and ERI complexes. However, their 
previously reported competitive inhibition patterns (K\ = 92 
μΜ) against varied [fructose] in triethanolamine buffer, p H 
7.4, do not accord with the present study. 
Table 1 

































































ΚΕ,Ι, ΚΕΟ,Ι and KERJ measure the affinity of SDI 158 for the free enzyme, the enzyme-NAD complex and the enzyme-NADH complex, respectively, 
and were derived from the slope and intercept effects in double-reciprocal plots with varied concentrations of NAD(H), sorbitol or fructose (see 
main text). The constants were determmed in 50 mM sodium phosphate, pH s 8.0, or 50 mM glycine/NaOH, pH a 9.0. ΚΕΙ,Ο and KEI,R measure 
the affinity of the coenzymes for the enzyme-inhibitor complex, and were calculated using the relationships KEi,o = ΚΕΟ,Ι·ΚΕ ,Ο/ΚΕ,Ι and 
KEI,R = KER,I -KEJR/KE II. The ratios Κ Ε / Κ Ε Ο , Ι (= Κ-Ε,Ο/ΚΕΙ,Ο) and ΚΕ,Ι/KER.I (= KE,R/KEI,R) reflect the relative stability of the ternary and binary 
complexes with SDI 158. n.s. = not kinetically significant. 
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Fig. 2. Schematic representation of putative interactions of SDI 158 
with sheep liver sorbitol dehydrogenase. Zn denotes the catalytic 
zinc atom, liganded by Cys43, His68 and Glu149 [3], and X represents 
an enzymic group suggested to be Glu154 and/or Lys293 (see text). In 
the enzyme bound binary or ternary complex, SDI 158 is coordi-
nated to zinc via N3 of the pyrimidine ring (A). Thus bound, SDI 
158 mimics sorbitol (B), which binds with the C2-OH coordinated 
to zinc and the Cl-OH interacting with Glul54 and/or Lys293 [4]. 
Kinetic data and the enzyme structure model [4] enable a 
rationalization of the interactions of SDI 158 with enzymic 
groups. As in the case of CNAD, a potent inhibitor of horse 
liver ADH [16], the primary interaction of inhibitory nitrogen, 
oxygen and sulphur nucleophiles with the related SDH can be 
expected to involve the catalytic zinc atom. The finding that 
piperazine (10 mM), dimethylsulfoxide [13] and various sul-
fonamides [12] have no significant inhibitory effect on SDH 
activity implies that the pyrimidine moiety of SDI 158 is co-
ordinated to zinc in the binary and ternary complexes. How-
ever, various pyrimidine derivatives and other heterocyclics 
are comparatively poor inhibitors of SDH [12,13] and, hence, 
the potent inhibition by SDI 158 indicates that factors other 
than binding to the catalytic metal are also involved in com-
plex formation with the enzyme. Two aspects of the structure 
of SDI 158 appear important in this respect. As shown by the 
poor inhibition by 2-methyl-4-(4-iVr,iV-dimethylaminosulfonyl-
1-piperazino) pyrimidine in vitro [10], the 2-hydroxymethyl 
substituent of SDI 158 is clearly a determinant for pyrimidine 
binding to zinc. According to the SDH structure model, 
Glu154 and/or Lys293 forms a specific hydrogen bond with 
the primary hydroxyl group adjacent to the C2-OH of sorbi-
tol, enabling the latter group to be poised for reaction at the 
catalytic zinc in the enzyme-NAD-sorbitol complex [4]. This is 
supported by site-directed mutagenesis studies [17], and by the 
fact that Bombyx mori SDH, which has a Gin residue in this 
position, shows an extremely low affinity for sorbitol [18]. A 
similar interaction appears involved also in the binding of 
various reversible inhibitors to the enzyme [12,13]. Hence, 
the binary and ternary complexes of sheep liver SDH with 
SDI 158 can be considered to involve an interaction of the 
2-hydroxymethyl moiety of the inhibitor with Glu154 and/or 
Lys293, and monodentate binding of the N3 of the pyrimidine 
moiety to zinc (Fig. 2). Thus bound at the bottom of the 
catalytic site, SDI 158 mimics a substrate. Furthermore, hy-
drophobic effects are likely to be involved in the binding of 
the largely non-polar ligand, as appears to be the case also 
with various substrates [12], reversible inhibitors [12,13] and 
affinity labelling reagents [19]. 
The pH dependence of the mixed inhibition of SDH by SDI 
158 reflects protonation/deprotonation of the inhibitor 
($>K=5.9) and of enzymic groups interacting with the inhib-
itor in the bound complexes. Formation of the EI, EOI and 
ERI complexes is inhibited by protonation and deprotonation 
of groups with, in the El complex, pK values of 6.6 (± 0.2) 
and 8.0 (±0.2), respectively. The former group is considered 
to be the pyrimidine moiety of SDI 158, perturbed by 0.7 unit 
upon formation of the El complex. Protonation of this group 
removes its metal chelating capability and, hence, inhibits 
complex formation with the enzyme at low pH. This parallels 
the pH dependence of the metal-directed affinity labelling of 
SDH by 2-bromo-3-(5-imidazolyl) propionic acid, which has 
been attributed to protonation of the imidazole moiety of the 
reagent (pK= 7.0) inhibiting its binding to zinc at low pH [20]. 
The pK 8.0 group is considered to be the water ligand to the 
catalytic zinc as, at high pH, a zinc bound hydroxide ion can 
be expected to repel the nitrogen nucleophile and thus inhibit 
binding. It appears that the pK of the enzymic group involved 
is perturbed to above 10 in the ERI complex. In the case of 
liver ADH, where the pK of the zinc-water ionization is per-
turbed to 11.2 upon binding of NADH [21], the differential 
effects of NAD and NADH on the ionization properties of 
the zinc-water ligand reflects stabilization and destabilization 
of zinc bound hydroxide by NAD and NADH, respectively. 
The previously reported mixed inhibition of SDH by thionu-
cleosides shows a similar pH dependence [12], suggesting a 
similar mechanism involving purine or pyrimidine binding to 
zinc in the binary or ternary complexes. 
Table 1 lists the ratios ΚΕ,Ι/ΚΕΟ,Ι (= ΚΕ,Ο/ΚΕΙ,Ο) and ΚΕ,Ι/ 
KER,I (= KE ,R/KEI,R) over the range pH 5.5-9.9. KER,I < KE,i 
and KEI,R < KE,R, reflecting stabilization of the ternary in re-
lation to the binary complexes. Similarly, the ternary com-
plexes with NAD are stabilized at pH > 7.4. This stabilization 
is likely to stem from a coenzyme- induced enzyme conforma-
tion change facilitating inhibitor binding in the catalytic site, 
as well as steric effects [12]. However, the tight binding of SDI 
158 to the free enzyme suggests that a coenzyme-induced con-
formation change may not be a prerequisite for binding. In-
terestingly, this structural transition upon coenzyme binding 
to the enzyme is induced by the nicotinamide part of NAD(H) 
[22]. The structurally similar pyrimidine moiety of SDI 158 
may enable tight binding in the catalytic domain of SDH, 
without prior coenzyme binding, by inducing a similar struc-
tural transition. The destabilization of the EOI complex at 
p H < 7 . 4 is likely to stem from unfavorable electrostatic in-
teraction of the bound coenzyme with the positively charged 
pyrimidine moiety of the inhibitor at low pH. Conversely, the 
stabilization of the EOI complexes with various thiol inhib-
itors has been attributed to thiolate inhibiting the release of 
coenzyme, and vice versa, from the ternary complexes [12]. 
The mixed inhibition of SDH by 6-thioinosine and 6-thio-
guanosine was previously interpreted in terms of EOI and 
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ERI ternary complexes giving rise to slope and intercept ef-
fects, respectively, in double-reciprocal plots with varied con-
centrations of sorbitol [12]. It is likely, that the inhibition by 
the thionucleosides also involves formation of El complexes 
and, hence, parallels that seen with SDI 158. Various other 
purine and pyrimidine derivatives, as well as polyol substrate 
analogues (e.g. 2-thiosorbitol), are expected to be potent in-
hibitors of SDH and, hence, interesting for further study and 
prospective clinical trials. As in the case of aldose reducíase 
[23], the elucidation of the sheep liver SDH crystal structure 
will enable design of enzyme inhibitors of optimal potency 
and specificity. 
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